BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 38551029)

  • 1. Exogenous glucagon-like peptide 2 counteracts exogenous cholecystokinin-induced gallbladder contraction in healthy men.
    Lange AH; Hansen NL; Pedersen MG; Nerild HH; Rehfeld JF; Hartmann B; Holst JJ; Ellegaard AM; Knop FK
    J Clin Endocrinol Metab; 2024 Jun; ():. PubMed ID: 38888179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass.
    Jonsson I; Bojsen-Møller KN; Kristiansen VB; Veedfald S; Wewer Albrechtsen NJ; Clausen TR; Kuhre RE; Rehfeld JF; Holst JJ; Madsbad S; Svane MS
    Front Endocrinol (Lausanne); 2021; 12():681116. PubMed ID: 34084153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
    Hansen M; Scheltema MJ; Sonne DP; Hansen JS; Sperling M; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2016 Jun; 18(6):571-80. PubMed ID: 26888164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.
    Beysen C; Murphy EJ; Deines K; Chan M; Tsang E; Glass A; Turner SM; Protasio J; Riiff T; Hellerstein MK
    Diabetologia; 2012 Feb; 55(2):432-42. PubMed ID: 22134839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.
    Dalsgaard NB; Gasbjerg LS; Hansen LS; Hansen NL; Stensen S; Hartmann B; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2021 Mar; 184(3):383-394. PubMed ID: 33449919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling.
    Gether IM; Bahne E; Nerild HH; Rehfeld JF; Hartmann B; Holst JJ; Vilsbøll T; Sonne DP; Knop FK
    Eur J Endocrinol; 2024 Mar; 190(4):314-326. PubMed ID: 38551029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
    Rohde U
    Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs.
    Gether IM; Nexøe-Larsen C; Knop FK
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2463-2472. PubMed ID: 30137354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Mar; 18(3):224-35. PubMed ID: 26500045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions - a narrative review.
    Huber H; Schieren A; Holst JJ; Simon MC
    Am J Clin Nutr; 2024 Mar; 119(3):599-627. PubMed ID: 38218319
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.